New Lyrica formulation performs in fibromyalgia, if not epilepsy; Congress at odds over FDA's role in compounding scandal;

@FiercePharma: New special report for a short week: The world's 20 best-selling generic drugs. Not just the usual suspects. Special Report | Follow @FiercePharma

> A controlled-release version of Pfizer's ($PFE) Lyrica fell short in a late-stage epilepsy trial, but proved helpful in fibromyalgia patients, according to top-line study results. Report

> FDA Commissioner Margaret Hamburg's appearance at a congressional hearing into the meningitis outbreak has triggered a debate over the agency's authority--or lack thereof--to police compounding pharmacies. Report

> Medicare's reimbursement policy on compounded drugs has been called into question in the wake of the meningitis outbreak linked to New England Compounding Center. Report

> The "party drug" Ecstasy, otherwise known as MDMA, has helped some U.S. veterans suffering from post-traumatic stress after fighting in Iraq and Afghanistan. Report

> Adding testosterone therapy to the erectile dysfunction drug Viagra doesn't improve performance any more than Viagra alone, a study found. Report

> India's Lupin launched a generic version of Abbott Laboratories' ($ABT) cholesterol pill TriCor. Report

Biotech News

 @FierceBiotech: GSK's new Promacta approval triggers a spike for Ligand shares. News | Follow @FierceBiotech

 @JohnCFierce: Celgene, Sanofi execs in (another) biopharma insider trading case. Is it that hard for insiders to get away with this? Story | Follow @JohnCFierce

 @RyanMFierce: Rare disease R&D and academic/pharma tie-up trends have melded in Shire's new alliance with Boston Children's. More | Follow @RyanMFierce

> Overnight success proves elusive for oral MS drugs. Item

> Review scolds FDA for lingering problems recruiting fresh talent. Story

Medical Device News

 @FierceMedDev: Spread the word - we're highlighting some of the top M&A targets in devices and diagnostics. Special Report | Follow @FierceMedDev

 @MarkHFierce: Could the device tax lead to supply problems? Item | Follow @MarkHFierce

 @DamianFierce: The SEC says employees of Stryker, Celgene and Sanofi carried on a complex insider trading scam. Report | Follow @DamianFierce

> Push to create pediatric medical devices brings Cincinnati Children's to Israel. Story

> Medtronic sees profit slip despite uptick in revenue. News

Biotech Research News

> Stem cells: A future treatment for Type 1 diabetes? News

> Northwestern U nanoparticle treats MS in mice. Article

> Radioactive injectable polymer safely kills tumors in mice. Story

> High risk of Alzheimer's disease linked to newly discovered gene mutation. Report

Pharma Manufacturing News

> Hikma temporarily closing West-Ward plant to fix new issues. Item

> Catalent cuts 45 at U.K. plant as demand 'changes'. Article

> Manufacturers return some drugs to market but shortages persist. News

> Feds probe if FedEx, UPS are delivery vehicles for illegal online pharmacies. Story

And Finally... Cue cute video: A paralyzed British daschund walks again after Cambridge University scientists use nose cells to bridge breaks in its spinal cord. Report

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.